Julia Van Steenhoven

Julia Van Steenhoven


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2020 in Histopathology
Verified
Journal Article
Open access
PDF file
JSJulia Van Steenhoven
Julia Van Steenhoven
AKAnne Kuijer
Anne Kuijer
RKRobert Kornegoor
Robert Kornegoor
GLGijs van Leeuwen
Gijs van Leeuwen
JGJoost van Gorp
Joost van Gorp
PDPaul J van Diest
Paul J van Diest
Aims: Phosphohistone H3 (PhH3) has been proposed as a novel proliferation marker in breast cancer. This study compares the interobserver agreement for assessment of the mitotic activity index (MAI), Ki67 expression, and PhH3 in a cohort of oestrogen receptor (ER)‐positive breast cancer patients.Methods and results: Tumour samples of 159 luminal breast cancer patients were collected. MAI and PhH3 scores were assessed by three breast cancer pathologists. Ki67 scores were assessed separately by two of the three pathologists. PhH3‐positive cells were counted in an area of 2 mm2, with a threshold of ≥13 positive cells being used to discriminate between low‐proliferative and high‐proliferative tumours. Ki67 expression was assessed with the global scoring method. Ki67 percentages of <20% were considered to be low. The intraclass correlation coefficient (ICC) and Cohen's κ statistics were used to evaluate interobserver agreement. The impact on histological grading of replacing the MAI with PhH3 was assessed. Counting PhH3‐positive cells was highly reproducible among all three observers (ICC of 0.86). The κ scores for the categorical PhH3 count (κ = 0.78, κ = 0.68, and κ = 0.80) reflected substantial agreement among all observers, whereas agreement for the MAI (κ = 0.38, κ = 0.52, and κ = 0.26) and Ki67 (κ = 0.55) was fair to moderate. When PhH3 was used to determine the histological grade, agreement in grading increased (PhH3, κ = 0.52, κ = 0.48, and κ = 0.52; MAI, κ = 0.43, κ = 0.35, and κ = 0.32), and the proportion of grade III tumours increased (14%, 18%, and 27%).Conclusion: PhH3 seems to outperform Ki67 and the MAI as a reproducible means to measure tumour proliferation in luminal‐type breast cancer. Variation in the assessment of histological grade might be reduced by using PhH3, but would result in an increase in the proportion of high‐grade cancers.

17 June 2019 in Annals of Surgical Oncology
Verified
Journal Article
Open access
PDF file
JSJulia Van Steenhoven
Julia Van Steenhoven
AKA. Kuijer
A. Kuijer
KSK. Schreuder
K. Schreuder
SES. G. Elias
S. G. Elias
PDP. J. van Diest
P. J. van Diest
TDT. van Dalen
T. van Dalen
We assessed the recent trends in the administration of adjuvant chemotherapy thereby evaluating the role of the 70-gene signature (70-GS) testing in decisi

20 March 2020 in Annals of Surgical Oncology
Verified
Journal Article
Open access
PDF file
JSJulia Van Steenhoven
Julia Van Steenhoven
AKAnne Kuijer
Anne Kuijer
MMMarissa C. van Maaren
Marissa C. van Maaren
MRMarleen Roos
Marleen Roos
SESjoerd G. Elias
Sjoerd G. Elias
TDThijs van Dalen
Thijs van Dalen
Background: Despite the potential for residual lymph node metastases after a negative or positive sentinel lymph node biopsy (SLNB), breast cancer patients rarely experience regional recurrences (RRs). This study aimed to quantify the effects of nonsurgical treatments on RR incidence among SLNB-negative (SLNB N0) breast cancer patients. Methods: All primary SLNB N0-staged breast cancer patients with a diagnosis between 2005 and 2008 and 5-year follow-up data on recurrences were selected from the Netherlands Cancer Registry. The cumulative incidence function (CIF) for RR was calculated as the first event at 5 years, taking into account any other first-event (local or distant recurrence, contralateral breast cancer, or death) as competing risk. Cox regression analysis was used to model the cause-specific hazard of RR developing as the first event to quantify the effect of adjuvant systemic therapy and whole-breast radiotherapy (RT) on RR incidence at 5 years. Results: The study included 13,512 patients. Of these patients, 162 experienced an RR. The CIF of RR at 5 years was 1.3% (95% confidence interval [CI], 1.1–1.5%), whereas the CIFs for death and other events were 4.4% and 9.5%, respectively. Cox regression analysis showed hazard ratios (HRs) of 0.46 (95% CI 0.33–0.64), 0.31 (95% CI 0.18–0.55), and 0.40 (95% CI 0.24–0.67) respectively for patients treated by RT as a routine part of breast-conserving therapy (BCT), chemotherapy, and hormonal therapy. Conclusion: RT as routine part of BCT, chemotherapy, and hormonal therapy independently exerted a mitigating effect on the risk for the development of RR. The three methods at least halved the risk.

17 May 2018 in Genes
Verified
Journal Article
Open access
PDF file
JSJulia Van Steenhoven
Julia Van Steenhoven
AKAnne Kuijer
Anne Kuijer
PDPaul J van Diest
Paul J van Diest
JGJoost M. Van Gorp
Joost M. Van Gorp
MSMarieke Straver
Marieke Straver
TDThijs Van Dalen
Thijs Van Dalen
In this study, in estrogen receptor positive (ER+) early stage breast cancer patients who were considered candidates for 70-gene signature (70-GS, “MammaPrint”) use, we compared molecular subtyping (MS) based on the previously validated 80-gene signature (80-GS, “BluePrint”) versus surrogate pathological subtyping (PS). Between 1 January 2013 and 31 December 2015, 595 clinical intermediate risk ER+ early stage breast cancer patients were enrolled. Hormone receptor (HR) and HER2 receptor status were determined by conventional pathology using immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH). Ki67 was assessed in a subset of patients. The overall concordance between PS and MS for luminal type cancers (A and B together) was 98%. The concordance between PS and MS for luminal A and luminal B type cancers based on the Bloom Richardson histological grade (BR) (n = 586) or Ki67 (n = 185) was low: 64% (Kappa 0.20 [95% CI 0.11–0.28]) and 65% (Kappa 0.22 [95% CI 0.062–0.37]), respectively. In this prospective study (NCT02209857) of a selection of ER+ and predominantly HER2− early-stage breast cancer patients, the additional ability of the 80-GS to distinguish between luminal, HER2-type and basal-like cancers was inherently very limited. The distinction of luminal-type tumors into A and B according to Ki67 status or BR grade versus the 70-GS revealed poor concordance.

27 June 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
SPSusana Patuleia
Susana Patuleia
CMCathy Moelans
Cathy Moelans
JKJasmijn Koopman
Jasmijn Koopman
JSJulia Van Steenhoven
Julia Van Steenhoven
TDThijs van Dalen
Thijs van Dalen
Karijn SuijkerbuijkKarijn Suijkerbuijk
Karijn Suijkerbuijk
Background: Nipple fluid aspiration (NFA) is a technique to acquire nipple aspirate fluid (NAF), which is considered a rich source of breast-specific biomarkers. Originating directly from the mammary ducts, this liquid biopsy can offer insight into the process of carcinogenesis at its earliest stage and therefore could be of added value to the current imaging-based breast cancer screening tools. With that in mind, it is necessary to know how well NFA is tolerated. Aim: To evaluate the participants’ tolerability of NFA compared to breast imaging screening methods and blood draws. Materials and methods: Three cohorts of women underwent NFA: healthy women (n = 190), women diagnosed with breast cancer (n = 137) and women at high risk of developing breast cancer (n = 48). A 0–10 discomfort score of NFA, mammography, breast MRI and blood draws, was filled in at the study visits, which took place once or annually. Results: The median discomfort rate of NFA was 1, which was significantly lower than the median discomfort of mammography and breast MRI (5 and 3, respectively, p < 0.001), but significantly higher than median discomfort for blood draws (0, p < 0.001). The great majority of women would undergo the procedure again (98%) and recommend it to others (97%). Conclusion: This study shows that NFA was well tolerated by healthy women, women diagnosed with breast cancer and high-risk women. This makes NFA a feasible method to pursue as a potential future breast cancer early detection tool, based on resident biomarkers. Trial registration: NL41845.041.12, NL57343.041.16 and NL11690.041.06 in trialregister.nl.

19 May 2020 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
JSJulia Van Steenhoven
Julia Van Steenhoven
BDBianca M. Den Dekker
Bianca M. Den Dekker
AKAnne Kuijer
Anne Kuijer
PDPaul J. van Diest
Paul J. van Diest
PNPeter Nieboer
Peter Nieboer
TDThijs van Dalen
Thijs van Dalen
Purpose: Little is known about the impact of 70-gene signature (70-GS) use on patients’ chemotherapy decision-making. The primary aim of this study was to evaluate the impact of 70-GS use on patients’ decisions to undergo chemotherapy. The perceived decision conflict during decision-making was a secondary objective of the study. Methods: Patients operated for estrogen receptor positive early breast cancer were asked to fill out a questionnaire probing their inclination to undergo chemotherapy before deployment of the 70-GS test. After disclosure of the 70-GS result patients were asked about their decision regarding chemotherapy. Patients’ decisional conflict was measured using the 16-item decisional conflict scale (DCS); scores < 25 are associated with a persuaded decision while a score > 37.5 implies that one feels unsure about a choice. Results: Between January 1th 2017 and December 31th 2018, 106 patients completed both questionnaires. Before deployment of the 70-GS, 58% of patients (n = 62) formulated a clear treatment preference, of whom 21 patients (34%) changed their opinion on treatment with chemotherapy following the 70-GS. The final decision regarding chemotherapy was in line with the 70-GS result in 90% of patients. The percentage of patients who felt unsure about their preference to be treated with chemotherapy decreased from 42 to 5% after disclosure of the 70-GS. The mean total DCS significantly decreased from pre-test to post-test from 35 to 23, irrespective of the risk estimate (p < 0.001). Conclusion: Deployment of the 70-GS changed patients’ inclination to undergo adjuvant chemotherapy in one third of patients and decreased patients’ decisional conflict.